Chuna Manual Therapy or Electroacupuncture with Pregabalin for Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Pilot Study.
Yeon-Woo LeeIlkyun LeeJin-Hyun LeeMin-Geun ParkJi Hoon KimYoon-Young SunwooMan-Suk HwangTae-Yong ParkPublished in: Journal of clinical medicine (2024)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects of chemotherapy, and effective treatments for CIPN are still lacking. For this reason, there is a growing interest in complementary and alternative medicine as a potential source of nonsurgical treatments for CIPN symptoms alongside pregabalin. One such option being explored is Chuna manual therapy (CMT), a traditional Korean manual therapy. Methods: This study compares the effectiveness and safety of using only pregabalin (PG) as a conventional method of treating breast and colorectal cancer patients with CIPN symptoms with a combination of both PG and electroacupuncture (EA) or CMT, while also assessing the feasibility of future large-scale clinical studies. Due to the COVID-19 pandemic, only 74 CIPN patients were recruited to this study. Twenty-five were assigned to the PG group, 26 to the PG + EA group, and 22 to the PG + CMT group for a five-week treatment and a four-week follow-up study. Results: For the primary outcome, we evaluated the mean differences in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) compared to the baseline at week 5 (visit 4). Although we found that the PG + CMT group showed the biggest difference (-16.64 [95% CI: -25.16, -8.11]) compared to the PG group (-8.60 [95% CI: -14.93, -2.27]) and the PG + EA group (-6.73 [95% CI: -12.34, -1.13]), this finding lacked statistical significance ( p = 0.2075). In terms of safety, two patients in the PG + CMT group reported side effects: one bruise and one headache. Conclusions: The low attrition and high adherence rates of all the groups, and the similar rates of side effects among them, support the feasibility of larger-scale follow-up studies.
Keyphrases
- chemotherapy induced
- end stage renal disease
- neuropathic pain
- cancer therapy
- chronic kidney disease
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- type diabetes
- prognostic factors
- drug delivery
- metabolic syndrome
- spinal cord injury
- risk assessment
- palliative care
- randomized controlled trial
- adipose tissue
- mesenchymal stem cells
- blood brain barrier
- replacement therapy
- weight loss
- smoking cessation
- current status
- patient reported
- glycemic control